Men who skip prostate screenings are 45% more likely to die from it.

Should we screen for every cancer? The surprising answer is no. 🚫 While screenings for breast, cervical, and colorectal cancers are public health pillars that save countless lives, the same cannot be said for all cancers. As a passionate advocate for evidence-based medicine, I find it crucial to understand that more screening is not always better. Why? Because for a population-wide screening program to be ethical and effective, the benefits must unequivocally outweigh the harms. Based on robust clinical trials and health economic data, here are cancers where routine screening for the general public is not recommended: 🦋 Thyroid Cancer:  Widespread screening leads to massive overdiagnosis of tiny, slow-growing tumors that would never cause harm. The resulting surgeries and treatments often do more damage than the cancer itself. 🪩 Pancreas & Ovarian Cancer:  For these, we lack a accurate, reliable test. Major trials (like UKCTOCS for ovarian cancer) showed that screening did not reduce deaths, but did lead to a high number of false positives and unnecessary, risky surgeries. ♣️ Testicular Cancer:  This cancer is highly curable even when found later. There's no evidence that routine screening improves the already excellent survival rates, but it can create significant anxiety and unnecessary procedures. The Key Takeaway:  The goal of smart healthcare isn't to find every cancer cell; it's to find the dangerous ones early, when treatment can save lives without causing unnecessary harm. This underscores the importance of following evidence-based guidelines and having open conversations with healthcare providers about personalized risk—not pursuing one-size-fits-all testing. What are your thoughts on the balance between early detection and overdiagnosis? #PublicHealth #PreventiveMedicine #Oncology #EvidenceBasedMedicine #PatientSafety #Healthcare #CancerScreening #MedicalGuidelines

Liver cancer cases are predicted to double by 2050, with mortality especially high in low- and middle-income countries (LMICs) and compounded by late diagnosis and limited management options. In liver cancer, multidisciplinary approach to treatment is vital. Yet, in many LMICs, multidisciplinary teams (MDTs) face barriers such as limited resources, training gaps, fragmented care pathways and lack of technology to support MDT efficiency. Overcoming these obstacles is critical, as MDTs have been shown to improve diagnosis accuracy, guide better treatment decisions and adherence to guidelines and increase survival, potentially by a third. At @AstraZeneca, we’re committed to work with partners to support health systems in training, infrastructure and technology improvement, so MDTs are empowered to deliver the right care at the right time, with the aim of transforming survival for patients with liver cancer. #AstraZeneca #LiverCancerAwarenessMonth

🎗️ 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗔 𝗚𝗹𝗼𝗯𝗮𝗹 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝗗𝗲𝗺𝗮𝗻𝗱𝗶𝗻𝗴 𝗖𝗼𝗼𝗿𝗱𝗶𝗻𝗮𝘁𝗲𝗱 𝗔𝗰𝘁𝗶𝗼𝗻  According to The Lancet Breast Cancer Commission, breast cancer is now the most diagnosed cancer worldwide, with 𝗼𝘃𝗲𝗿 3 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗻𝗲𝘄 𝗰𝗮𝘀𝗲𝘀 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗮𝗻𝗻𝘂𝗮𝗹𝗹𝘆 𝗯𝘆 2040. The burden will disproportionately affect low- and middle-income countries, where access to screening and care remains limited. 📉 𝗗𝗲𝘀𝗽𝗶𝘁𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝘀, 𝗶𝗻𝗲𝗾𝘂𝗶𝘁𝗶𝗲𝘀 𝗶𝗻 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴, 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀, 𝗮𝗻𝗱 𝘀𝘂𝗿𝘃𝗶𝘃𝗼𝗿𝘀𝗵𝗶𝗽 𝗽𝗲𝗿𝘀𝗶𝘀𝘁—𝗯𝗼𝘁𝗵 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗮𝗻𝗱 𝘄𝗶𝘁𝗵𝗶𝗻 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀. 🇪🇺 That’s where 𝗝𝗔𝗡𝗘-2 steps in. As part of Europe’s Beating Cancer Plan, JANE-2 is building Networks of Expertise to tackle these gaps head-on. 🔬 From personalized prevention to survivorship and palliative care, JANE-2 is:  ✅ 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 disparities across Europe  ✅ 𝗣𝗿𝗼𝗺𝗼𝘁𝗶𝗻𝗴 evidence-based screening strategies  ✅ 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 digital innovation and AI integration  ✅ 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 collaboration between Member States  ✅ 𝗖𝗿𝗲𝗮𝘁𝗶𝗻𝗴 sustainable tools for long-term impact 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝘄𝗲 𝗮𝗿𝗲 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘁𝗼 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗮𝘁 𝗻𝗼 𝗼𝗻𝗲 𝗶𝘀 𝗹𝗲𝗳𝘁 𝗯𝗲𝗵𝗶𝗻𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗶𝗴𝗵𝘁 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿. The Lancet Breast Cancer Commission. Breast cancer: global quality care optimising care across the globe. The Lancet. 2023;402(10403):1233–1288. Available from: https://lnkd.in/dECJrCEe #BreastCancer #JANE2 #CancerPrevention #EUHealth #HealthEquity #DigitalHealth #Oncology #LancetCommission #CancerScreening #PublicHealth #EU4Health #HaDEA #EUHealthNetworks 

🌏 China’s Lung Cancer Screening Market: A Rapidly Evolving Landscape Lung cancer remains one of the deadliest diseases in China, claiming over 700,000 lives annually. Early detection is no longer optional—it’s critical. With the integration of Low-Dose CT (LDCT) scans, AI-assisted diagnostics, and government-backed screening programs, China is witnessing a significant shift toward earlier, more treatable lung cancer diagnoses. 📈 Market Insights: Market projected to reach US$ 1,295.5 Mn by 2032 from US$ 616.2 Mn in 2025, growing at a CAGR of 11.2%. LDCT expected to hold ~71% share in 2025, thanks to its high sensitivity for early-stage cancers. Non-Small Cell Lung Cancer (NSCLC) dominates, with adenocarcinoma on the rise, especially in non-smoking populations. 💡 Opportunities: AI-driven image analysis is improving detection accuracy and reducing radiologist workload. Provincial programs in Shandong, Sichuan, and Jiangsu are setting new benchmarks for accessibility, awareness, and uptake. Mobile CT solutions and tele-radiology are bridging regional gaps, bringing screening to underserved areas. ⚠️ Challenges: Low uptake and high false-positive rates still limit program effectiveness. Awareness and health literacy remain critical factors to increase compliance among high-risk populations. The China lung cancer screening market is not just about technology—it’s about saving lives through early detection, equitable access, and innovative healthcare solutions. Read More: https://lnkd.in/dxffMNvz #HealthcareInnovation #LungCancerAwareness #MedicalImaging #AIinHealthcare #EarlyDetection #ChinaHealthcare

Researchers are repurposing the herpes simplex virus (HSV-1)—long associated with cold sores—into a revolutionary oncolytic virus that directly attacks cancer. Engineered strains like RP1 and RP2 are designed to infiltrate tumors, replicate inside them, and cause cancer cells to rupture while simultaneously awakening the body’s immune system to target cancer elsewhere. Early clinical trials are showing striking results: about 25% of advanced cancer patients responded, while nearly one in three melanoma patients saw tumor shrinkage, and one in six achieved complete remission. Side effects have mostly been mild, flu-like symptoms, making the treatment relatively well tolerated. With larger Phase 3 trials underway, this viral “Trojan horse” approach could mark the beginning of a new era in oncology—where viruses not only destroy tumors but also reprogram the immune system for long-lasting defense. hashtag #CancerResearchhashtag #OncolyticVirushashtag #HSV1hashtag #Immunotherapyhashtag #MedicalBreakthrough Stay connected and Updated With DOCTOR OF PHARMACY ASSOCIATION (W.B) 🔗Facebook - https://lnkd.in/gPRNiWKu 🔗 Linkdin - https://lnkd.in/gd3zcFpe 🔗 Instagram - https://lnkd.in/g47zBwHi 💌 Mail- associationdoctorofpharmacy@gmail.com 🎓 Important for Pharm D students and Professionals community1️⃣ : https://lnkd.in/gEZXtnna Community2️⃣: https://lnkd.in/g8QX_b2U

💡 A single blood test that detects dozens of cancers — many with no current screening options. GRAIL’s PATHFINDER 2 results show just how transformational this could be. Adding the Galleri® multi-cancer early detection (MCED) test to standard screenings increased overall cancer detection by more than sevenfold. Key insights from nearly 35,900 adults aged 50+: >7× increase in cancers found >50% detected at early (I–II) stages ~99.6% specificity ~92% accuracy in identifying the cancer’s origin ~75% of cancers detected had no recommended screening test This isn’t just a scientific milestone — it’s a signal that healthcare is shifting from reactive treatment to proactive prevention. We’ve spent decades building systems to manage disease. The next decade will be about anticipating it — leveraging data, biology, and innovation to intervene earlier than ever before. #HealthcareInnovation #CancerScreening #ValueBasedCare #HealthTech #NHS #ESMO 🔗 Read the full announcement: https://lnkd.in/evVxnTTd

We’re pleased to share our recently published letter to the editor in Gaceta Sanitaria, advocating for more accurate and timely evaluations to guide lung cancer screening policy in Spain. This joint response reflects a strong commitment to evidence-based decision-making and marks an important step forward in aligning public health strategies with real-world data—especially through the work of the CASSANDRA project. Read more: https://lnkd.in/gx24-_dD #HealthEconomics #LungCancerScreening #PublicHealth #CASSANDRAproject #EvidenceBasedPolicy

𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗕𝗹𝗼𝗼𝗱 𝗧𝗲𝘀𝘁 𝗗𝗲𝘁𝗲𝗰𝘁𝘀 𝗛𝗲𝗮𝗱 𝗮𝗻𝗱 𝗡𝗲𝗰𝗸 𝗖𝗮𝗻𝗰𝗲𝗿 𝘂𝗽 𝘁𝗼 𝟭𝟬 𝗬𝗲𝗮𝗿𝘀 𝗕𝗲𝗳𝗼𝗿𝗲 𝗦𝘆𝗺𝗽𝘁𝗼𝗺𝘀 Head and neck cancers are notoriously difficult to treat though a Rexpharma QP is currently releasing a novel clinical treatment into that space. Human papillomavirus (HPV) is responsible for about 70% of head and neck cancers in the United States, making it the most common type of cancer linked to the virus. Rates of these cancers continue to rise each year. Unlike HPV-related cervical cancers, which have established screening options, there is currently no test to detect HPV-associated head and neck cancers. As a result, most cases are diagnosed only after tumors have already expanded to billions of cells, causing symptoms and often spreading to nearby lymph nodes. Developing screening tools that can identify these cancers much earlier would allow patients to begin treatment sooner and improve outcomes. Mass General Brigham’s new HPV-DeepSeek test enables much earlier cancer detection through a blood sample, creating a new opportunity for screening HPV-related head and neck cancers up to 10 years before they clinically present. More at: www.rexpharma.ie https://lnkd.in/eSzP-Abk. Rexpharma Limited (EU QP Service) Mass General Brigham Mass General Brigham Innovation #ATMP #HPV #HSV #headandneck #cancer #cancerscreening #QP #qualifiedperson #audit #consultant #consulting #screening #QPs

🔬 Remarkable strides and urgent gaps in the fight against lung cancer   Over the last decade, we’ve witnessed a transformation in the lung cancer treatment landscape. But despite these advances, many patients and families are still left with unmet needs. Let´s have a look at it:   From one-size-fits-all to precision medicine Thanks to targeted therapies and immunotherapies, we are now routinely matching treatments to molecular profiles (EGFR, ALK, ROS1, KRAS, etc.). These “precision” approaches have significantly improved survival, even for metastatic non-small cell lung cancer. These advances underscore that lung cancer is no longer a monolithic disease - we are steadily turning it into a constellation of molecularly defined subtypes, each with its own therapeutic roadmap.   But the unmet need is still very high Studies show that ~80% of lung cancer patients report at least one unmet supportive care need, with psychological and informational needs being among the most common.  In short: even as we unlock more precise therapies, many patients and caregivers are left navigating emotional, social, and practical challenges - sometimes far beyond what the clinic can deliver.   💡 Bottom line (for me and, I hope, for us all): We must continue pushing the frontier of innovative therapies - but we cannot forget the human side. Research, policy, and care models need to evolve in parallel: to anticipate and deliver on what patients and families truly need.   If you’re working in lung cancer care, research, patient advocacy, or policy, I’m always eager to connect and learn: See you hopefully at ESMO congress in Berlin!   #LungCancer #MyCompany #PrecisionMedicine #Oncology #PatientCare #ESMO26 #CancerResearch #FlatWhiteBerlin